DCDenise Pontes Cavalcanti

Denise Pontes Cavalcanti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denise Pontes Cavalcanti has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction: Skeletal dysplasias of the parathyroid hormone signaling cascade: radiological manifestations and molecular mechanisms

    by Yuko Tsujioka, Atsuhiko Handa, Alistair D. Calder, Denise P. Cavalcanti, Ekkehart Lausch, Ok Hwa Kim, Tomonobu Hasegawa, Chikahiko Numakura, Masahiro Jinzaki, Gen Nishimura, et al.

  • Open Access

    Whole Genome Sequencing for the Diagnosis of Rare Disorders

    by Antonio Victor Campos Coelho, Rafael Sales de Albuquerque, Catarina dos Santos Gomes, Jose Bandeira Do Nascimento Junior, Gustavo Santos de Oliveira, Livia Maria Silva Moura, Luciana Souto Mofatto, Rafael Lucas Muniz Guedes, Rodrigo Araujo Sequeira Barreiro, Marcel Pinheiro Caraciolo, et al.

    Background: Whole-Genome Sequencing (WGS) and Whole-Transcriptome Sequencing (WTS) have emerged as transformative tools in the diagnosis of rare diseases with complex phenotypes. These technologies enable deep analysis of the genome and RNA expression, uncovering structural, intronic, non-coding, and mitochondrial variants that traditional methods might miss, thus facilitating the understanding of gene function and regulation. Methods: We enrolled 8966 patients with suspected rare diseases or hereditary cancer risk syndromes from 21 centers throughout Brazil. Their genomes were sequenced with short, paired-end reads, and diagnostic reports were provided for 7614 of these patients. Results: The overall diagnostic yield was 35.8%, with an additional 5.6% of all Positive reports including gains from WGS compared to other diagnostic tests. In patients with pathogenic/likely pathogenic copy number or structural variants, WGS provided a 10.2% increase in diagnostic yield. Almost 1900 variant/phenotype interpretations were submitted to ClinVar. Conclusion: WGS and WTS are proving to be invaluable resources for shortening the diagnostic odyssey of patients with rare diseases, providing crucial genomic diagnostics, and enriching genetic databases with variant interpretations from underrepresented populations. These technologies have the potential to significantly enhance the precision of healthcare in genetically diverse populations. Key Points for NEJM Editors and Reviewers: Scope : Largest Brazilian rare disease–focused sequencing project to date. Findings : A 35.8% diagnostic yield with notable additional detection of structural, deep intronic, non-coding, and mitochondrial variants. Impact : Shortens diagnostic odyssey for patients, enriches ClinVar with almost 1900 variant interpretations from underrepresented populations, and demonstrates potential cost-effectiveness of integrating WGS into public healthcare. These interim results underscore how national WGS programs can facilitate precision medicine, especially in genetically diverse and previously underrepresented populations.


  • A mesomelic skeletal dysplasia, Kantaputra‐like, not related to HOXD cluster region, and with phenotypic gender differences

    by Maria Dora Jazmin Lacarrubba‐Flores, Karina da Costa Silveira, Cynthia Silveira, Benilton S. Carvalho, Denise Pontes Cavalcanti

    Mesomelic skeletal dysplasia is a heterogeneous group of skeletal disorders that has grown since the molecular basis of these conditions is in the process of research and discovery. Here, we report a Brazilian family with eight affected members over three generations with a phenotype similar to mesomelic Kantaputra dysplasia. This family presents marked shortening of the upper limbs with hypotrophy of the lower limbs and clubfeet without synostosis. Array‐based CNV analysis and exome sequencing of four family members failed to show any region or gene candidate. Interestingly, males were more severely affected than females in this family, suggesting that gender differences could play a role in the phenotypic expressivity of this condition.


  • Open Access

    CYP26B1-related disorder: expanding the ends of the spectrum through clinical and molecular evidence

    by Karina C. Silveira, Inara Chacon Fonseca, Connor Oborn, Parker Wengryn, Saima Ghafoor, Alexander Beke, Ema S. Dreseris, Cassandra Wong, Aline Iacovone, Carrie-Lynn Soltys, et al.

    CYP26B1 metabolizes retinoic acid in the developing embryo to regulate its levels. A limited number of individuals with pathogenic variants in CYP26B1 have been documented with a varied phenotypic spectrum, spanning from a severe manifestation involving skull anomalies, craniosynostosis, encephalocele, radio-humeral fusion, oligodactyly, and a narrow thorax, to a milder presentation characterized by craniosynostosis, restricted radio-humeral joint mobility, hearing loss, and intellectual disability. Here, we report two families with CYP26B1-related phenotypes and describe the data obtained from functional studies of the variants. Exome and Sanger sequencing were used for variant identification in family 1 and family 2, respectively. Family 1 reflects a mild phenotype, which includes craniofacial dysmorphism with brachycephaly (without craniosynostosis), arachnodactyly, reduced radioulnar joint movement, conductive hearing loss, learning disability—and compound heterozygous CYP26B1 variants: (p.[(Pro118Leu)];[(Arg234Gln)]) were found. In family 2, a stillborn fetus presented a lethal phenotype with spina bifida occulta, hydrocephalus, poor skeletal mineralization, synostosis, limb defects, and a synonymous homozygous variant in CYP26B1: c.1083C > A. A minigene assay revealed that the synonymous variant created a new splice site, removing part of exon 5 (p.Val361_Asp382del). Enzymatic activity was assessed using a luciferase assay, demonstrating a notable reduction in exogenous retinoic acid metabolism for the variant p.Val361_Asp382del. (~ 3.5 × decrease compared to wild-type); comparatively, the variants p.(Pro118Leu) and p.(Arg234Gln) demonstrated a partial loss of metabolism (1.7× and 2.3× reduction, respectively). A proximity-dependent biotin identification assay reaffirmed previously reported ER-resident protein interactions. Additional work into these interactions is critical to determine if CYP26B1 is involved with other biological events on the ER. Immunofluorescence assay suggests that mutant CYP26B1 is still localized in the endoplasmic reticulum. These results indicate that novel pathogenic variants in CYP26B1 result in varying levels of enzymatic activity that impact retinoic acid metabolism and relate to the distinct phenotypes observed.


  • Open Access

    SLC26A2/DTDST Spectrum: A Cohort of 12 Patients Associated with a Comprehensive Review of the Genotype-Phenotype Correlation

    by Cynthia Silveira, Karina da Costa Silveira, Maria D. Lacarrubba-Flores, Maurício T. Sakata, Silvia N. Carbognani, Juan Llerena Jr., Carolina A. Moreno, Denise P. Cavalcanti

    Introduction: Pathogenic variants in the SLC26A2/DTDST gene cause the following spectrum of phenotypes: achondrogenesis 1B (ACG1B), atelosteogenesis 2 (AO2), diastrophic dysplasia (DTD), and recessive-multiple epiphyseal dysplasia (rMED), the first 2 being lethal. Here, we report a cohort and a comprehensive literature review on a genotype-phenotype correlation of SLC26A2/DTDST-related disorders. Methods: The local patients were genotyped by Sanger sequencing or next-generation sequencing (NGS). We reviewed data from the literature regarding phenotype, zygosity, and genotype in parallel. Results: The local cohort enrolled 12 patients, including one with a Desbuquois-like phenotype. All but one showed biallelic mutations, however, only one allele mutated in a fetus presenting ACG1B was identified. The literature review identified 42 articles and the analyses of genotype and zygosity included the 12 local patients. Discussion: The R279W variant was the most prevalent among the local patients. It was in homozygosity (hmz) in 2 patients with rMED and in compound heterozygosity (chtz) in 9 patients. The genotype and zygosity review of all patients led to the following conclusions: DTD is the most common phenotype in Finland due to a Finnish mutation (c.727–1G>C). Outside of Finland, rMED is the most prevalent phenotype, usually associated with R279W in hmz. In contrast, DTD’s genotype is usually in chtz. Despite a large number of variants (38), just 8 are recurrent (R279W, C653S, c.−26+2T>C, R178*, K575Sfs*10, V340del, G663R, T512K). The last 3 in hmz lead to lethal phenotypes. The Finnish mutation is found only in chtz outside of Finland, being associated with all 4 classical phenotypes. The p.R178* and p.K575Sfs*10 variants should be viewed as lethal mutations since both were mainly described with lethal phenotypes and were never reported in hmz. The existence of 9 patients with only one mutated allele suggests that other mutations in the other allele of these patients still need to be unveiled.


  • Molecular diagnosis in a cohort of 114 patients with rare skeletal dysplasias

    by Karina C. Silveira, Thatiane Y. Kanazawa, Cynthia Silveira, Maria D. J. Lacarrubba‐Flores, Benilton S. Carvalho, Denise P. Cavalcanti

    Molecular diagnosis is important to provide accurate genetic counseling of skeletal dysplasias (SD). Although next‐generation sequencing (NGS) techniques are currently the preferred methods for analyzing these conditions, some of the published results have not shown a detection rate as high as it would be expected. The present study aimed to assess the diagnostic yield of targeted NGS combined with Sanger sequencing (SS) for low‐coverage exons of genes of interest and exome sequencing (ES) in a series of patients with rare SD and use two patients as an example of our strategy. This study used two different in‐house panels. Of 93 variants found in 88/114 (77%) patients, 57 are novel. The pathogenic variants found in the following genes: B3GALT6, PCYT1A, INPPL1, LIFR, of four patients were only detected by SS. In conclusion, the high diagnostic yield reached in the present study can be attributed to both a good selection of patients and the utilization of the SS for the insufficiently covered regions. Additionally, the two case reports—a patient with acrodysostosis related to PRKAR1A and another with ciliopathy associated with KIAA0753, add new and relevant clinical information to the current knowledge.


  • Open Access

    New SHH and Known SIX3 Variants in a Series of Latin American Patients with Holoprosencephaly

    by Viviane Freitas de Castro, Daniel Mattos, Flavia Martinez de Carvalho, Denise Pontes Cavalcanti, Milagros M. Duenas-Roque, Juan Llerena Jr, Viviana Raquel Cosentino, Rachel Sayuri Honjo, Julio Cesar Loguercio Leite, Maria Teresa Sanseverino, et al.

    Holoprosencephaly (HPE) is the failure of the embryonic forebrain to develop into 2 hemispheres promoting midline cerebral and facial defects. The wide phenotypic variability and causal heterogeneity make genetic counseling difficult. Heterozygous variants with incomplete penetrance and variable expressivity in the SHH, SIX3, ZIC2, and TGIF1 genes explain ∼25% of the known causes of nonchromosomal HPE. We studied these 4 genes and clinically described 27 Latin American families presenting with nonchromosomal HPE. Three new SHH variants and a third known SIX3 likely pathogenic variant found by Sanger sequencing explained 15% of our cases. Genotype-phenotype correlation in these 4 families and published families with identical or similar driver gene, mutated domain, conservation of residue in other species, and the type of variant explain the pathogenicity but not the phenotypic variability. Nine patients, including 2 with SHH pathogenic variants, presented benign variants of the SHH, SIX3, ZIC2, and TGIF1 genes with potential alteration of splicing, a causal proposition in need of further studies. Finding more families with the same SIX3 variant may allow further identification of genetic or environmental modifiers explaining its variable phenotypic expression.


  • Skeletal dysplasias in Latin America

    by Denise P. Cavalcanti, Virginia Fano, Cecilia Mellado, Maria Dora J. Lacarrubba‐Flores, Cynthia Silveira, Karina C. Silveira, Mariana del Pino, Angelica Moresco, Silvia Caino, Rosario Ramos Mejía, et al.

    Skeletal dysplasias (SD) are disturbances in growth due to defects intrinsic to the bone and/or cartilage, usually affecting multiple bones and having a progressive character. In this article, we review the state of clinical and research SD resources available in Latin America, including three specific countries (Brazil, Argentina, and Chile), that have established multidisciplinary clinics for the care of these patients. From the epidemiological point of view, the SD prevalence of 3.2 per 10,000 births from nine South American countries included in the ECLAMC network represents the most accurate estimate not just in Latin America, but worldwide. In Brazil, there are currently five groups focused on SD. The data from one of these groups including the website www.ocd.med.br, created to assist in the diagnosis of SD, are highlighted showing that telemedicine for this purpose represents a good strategy for the region. The experience of more than 30 years of the SD multidisciplinary clinic in an Argentinian Hospital is presented, evidencing a solid experience mainly in the follow‐up of the most frequent SD, especially those belonging the FGFR3 group and OI. In Chile, a group with 20 years of experience presents its work with geneticists and pediatricians, focusing on diagnostic purposes and clinical management. Altogether, although SD health‐care and research activities in Latin America are in their early stages, the experience in these three countries seems promising and stimulating for the region as a whole.


  • Open Access

    Identification of genomic imbalances in oral clefts

    by Elaine Lustosa-Mendes, Ana P. dos Santos, Társis P. Vieira, Erlane M. Ribeiro, Adriana A. Rezende, Agnes C. Fett-Conte, Denise P. Cavalcanti, Têmis M. Félix, Isabella L. Monlleó, Vera Lúcia Gil-Da-Silva-Lopes


  • Pathogenic variants in theTRIP11gene cause a skeletal dysplasia spectrum from odontochondrodysplasia to achondrogenesis 1A

    by Cristina T. N. Medina, Renata Sandoval, Gabriela Oliveira, Karina da Costa Silveira, Denise P. Cavalcanti, Robert Pogue

    The thyroid hormone receptor interactor 11 (TRIP11) gene encodes the Golgi microtubule‐associated protein 210 (GMAP‐210), a protein essential for the operation of the Golgi apparatus. It is known that null mutations inTRIP11disrupt Golgi function and cause a lethal skeletal dysplasia known as achondrogenesis type 1A (ACG1A), however recently, hypomorphic mutations in that gene have been linked to odontochondrodysplasia (ODCD), a nonlethal skeletal dysplasia characterized by skeletal changes in the spine and in the metaphyseal regions, associated with dentinogenesis imperfecta. Here we present two patients reflecting the phenotypic spectrum related to differentTRIP11variants. The first is a female child with ODCD, for whom a homozygous in‐frame splicing mutation in intron 9 ofTRIP11was identified. The mutation appears to lead to the expression of an alternative TRIP11 transcript, that may explain the less severe radiological alterations in ODCD. The second is a fetus with classical form of ACG1A, associated with typical molecular findings (frameshift) in exon 11 ofTRIP11,both novel mutations. The two patients reported here represent theTRIP11spectrum of skeletal dysplasia ranging from mild to lethal phenotypes, thereby enabling one to suggest a genotype–phenotype correlation in these diseases.